Fourteen Current and Former Affy Officials Named In Shareholder Suit for Backdating Stock Option Grants | GenomeWeb
Affymetrix and more than a dozen of its current and former officials are being sued by a shareholder for allegedly backdating grants of stock options, taking tax deductions based on those stock options, and making false statements related to the granting of those options.
 
The company disclosed in a filing with the US Securities and Exchange Commission last week that it has been named in the shareholder derivative suit, which is pending in the United States District Court for the Northern District of California.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.